Patent application number | Description | Published |
20160141012 | MANAGING SKEW IN DATA SIGNALS - An apparatus for controlling memory includes a memory controller, and an interface to data lines connecting it to memory. Each line carries a signal that corresponds to a bit to be written to memory. The interface includes, for each line, circuitry for transmitting a bit to memory via the line, and a data de-skewer. For each line, the de-skewer receives a first data signal that represents a bit to be written. Each line has an inherent skew. The de-skewer generates a second data signal by applying a skew to the first. A selected extent of skew increases a likelihood of sampling the second data signal during a data-valid window thereof. The same de-skewer receives and skews a first data bit read from the memory. | 05-19-2016 |
20160141013 | MANAGING SKEW IN DATA SIGNALS WITH ADJUSTABLE STROBE - An apparatus for controlling memory includes a memory controller, and a data interface that interfaces with and is in data communication with data lines, each having inherent skew. Each data line carries a data signal. The data lines connect the memory controller to the memory. The apparatus also includes data de-skewers, each associated with a corresponding data line, a strobe interface that interfaces with a strobe line that connects the memory controller to the memory and that applies a timing signal to the strobe line, and a strobe de-skewer connected to the strobe line. Each data de-skewer operates in read or write mode. A particular data line's data de-skewer applies a compensation skew to a data signal carried by that line. | 05-19-2016 |
20160141016 | CONTROLLED MULTI-STEP DE-ALIGNMENT OF CLOCKS - An apparatus for data processing includes first and second functional units driven by corresponding first and second clock-signal sources, and a clock-retardation unit. The clock-retardation unit is configured to cause the second clock-signal to sustain a temporal offset that causes an offset between the first and second clock-signals to step toward a target time-domain offset between the first and second clock-signals. | 05-19-2016 |
20160141017 | CONTROLLED DYNAMIC DE-ALIGNMENT OF CLOCKS - A controller includes first and second functional units, first and second clock-signal sources that provide corresponding first and second clock signals that drive the first and second functional units respectively. The second clock-signal generates its second clock-signal based on the first clock-signal. The clock-retardation unit dynamically causes the second clock-signal to have a target time-domain offset relative to the first clock-signal. | 05-19-2016 |
20160141018 | MANAGING SKEW IN DATA SIGNALS WITH MULTIPLE MODES - A method for controlling a memory includes causing a data de-skewer to operate in a writing mode, at the data de-skewer, receiving a first signal, and skewing the first data signal by a first compensation skew, causing the data de-skewer to operate in a reading mode, at the data de-skewer, receiving a second signal, and skewing the second signal by a second compensation skew, wherein the first signal is representative of a bit from a byte that is to be written to the memory, and wherein the second signal is representative of a bit from a byte that has been read from the memory. | 05-19-2016 |
Patent application number | Description | Published |
20100068289 | SPHERICAL MICROCAPSULES COMPRISING GLP-I PEPTIDES, THEIR PRODUCTION AND USE - The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present application is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapsules e.g. in the treatment of type 2 diabetes, weight disorders and diseases or conditions associated thereto, neurodegenerative disorders and diseases or conditions associated thereto, or for the treatment of disorders and diseases or conditions associated to apoptosis. | 03-18-2010 |
20100160556 | GLP-1 Fusion Peptides Conjugated to Polymer(s), Their Production and Use - The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV conjugated to polymers, thereby forming conjugate molecules. The fusion peptide of the conjugate molecule comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. A synthetic polymer and/or a protein, e.g transferrin or albumin, is covalently or non-covalently bound to the fusion peptide to form the conjugate molecule. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2 and a polymeric component, e.g. a natural or non-natural polymer. The fusion peptide may be produced in engineered cells or synthetically and is e.g. conjugated to the polymeric component by chemical synthesis. The conjugate molecule may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. | 06-24-2010 |
20110130329 | Glp-1 Fusion Peptides, Their Production and Use - The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. | 06-02-2011 |
20110236431 | TREATMENT OF ACUTE MYOCARDIAL INFARCTION (AMI) USING ENCAPSULATED CELLS ENCODING AND SECRETING GLP-1 PEPTIDES OR ANALOGS THEREOF - The present application refers to the use of cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, for the treatment of acute myocardial infarction (AMI or Ml), wherein the cells, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, are encapsulated in a (spherical) microcapsule to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or of a pharmaceutical composition containing these cells or (spherical) microcapsule(s) for the treatment of acute myocardial infarction (AMI or Ml). | 09-29-2011 |
20120238497 | GLP-1 FUSION PEPTIDES, THEIR PRODUCTION AND USE - The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for preparing a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. | 09-20-2012 |
20120263794 | TREATMENT OF EYE DISEASES USING ENCAPSULATED CELLS ENCODING AND SECRETING A NEUROPROTECTIVE FACTOR AND/OR AN ANTI-ANGIOGENIC FACTOR - The present application refers to cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting a neuroprotective factor, an anti-angiogenic factor and/or any other protein or protein-like substance suitable for (intraocular) treatment of eye diseases. Such eye diseases include glaucoma and other optic nerve disorders, retinal diseases, particularly retinitis pigmentosa (RP), age-related macular degeneration (AMD) and diabetic retinopathy, etc. The cells used herein are encapsulated in a (spherical) microcapsule, preferably comprising a core and at least one surface layer, to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or such factors for (intraocular) treatment of eye diseases as defined herein (for the preparation of a (pharmaceutical) composition) for the treatment of such eye diseases. | 10-18-2012 |
20140105991 | SPHERICAL MICROCAPSULES COMPRISING GLP-1 PEPTIDES, THEIR PRODUCTION AND USE - The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present applicators is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapules e.g. in the treatment of type 2 diabetes, weight disorders and diseases or conditions associated thereto, neurodegenerative disorders and diseases or conditions associated thereto, or for the treatment of disorders and diseases or conditions associated to apoptosis. | 04-17-2014 |